医学
急性肾损伤
生物标志物
重症监护医学
2019年冠状病毒病(COVID-19)
肾脏疾病
败血症
疾病
大流行
内科学
生物信息学
作者
Lianjiu Su,Jiahao Zhang,Zhiyong Peng
出处
期刊:Renal Failure
[Informa]
日期:2022-12-01
卷期号:44 (1): 1280-1288
标识
DOI:10.1080/0886022x.2022.2107544
摘要
The coronavirus disease-2019 (COVID-19) outbreak has been declared a global pandemic. COVID-19-associated acute kidney injury (COVID-19 AKI) is related to a high mortality rate and serves as an independent risk factor for hospital death in patients with COVID-19. Early diagnosis would allow for earlier intervention and potentially improve patient outcomes. The goal of early identification of AKI has been the primary impetus for AKI biomarker research, and several kidney injury biomarkers have been demonstrated to be beneficial in predicting COVID-19 AKI as well as disease progression in COVID-19. Furthermore, such data provide valuable insights into the molecular mechanisms underlying this complex and unique disease and serve as a molecular phenotyping tool that could be utilized to direct clinical intervention. This review focuses on a number of kidney injury biomarkers, such as CysC, NAGAL, KIM-1, L-FABP, IL-18, suPAR, and [TIMP-2] • [IGFBP7], which have been widely studied in common clinical settings, such as sepsis, cardiac surgery, and contrast-induced AKI. We explore the role of kidney injury biomarkers in COVID-19 and discuss what remains to be learned.
科研通智能强力驱动
Strongly Powered by AbleSci AI